PrEP

Other topics in this section

PrEP: latest news

PrEP resources

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • HIV drug discovery puts licensing pressure on govt

    A breakthrough joint medical study on an anti-Aids drug by the US and Bangkok City Hall has highlighted the need to address again the problem with health costs and, more importantly, the politically toxic issue of compulsory licensing.

    17 June 2013 | Bangkok Post

  • Beyond the Hype: PrEP for People Who Inject Drugs

    While the results of the Bangkok Tenofovir Study are striking, so is the difficulty of assessing the relevance of these clinical trial results for most of the world.

    17 June 2013 | Huffington Post

  • New PrEP Trial Results Among Injecting Drug Users Underscore That PrEP Works When Taken Consistently; AVAC Calls for Accelerated Action to Get PrEP to Those Who Can Benefit From It

    "This is the first trial to provide evidence for a prevention option that could protect against HIV infection through both sexual contact and injecting drug use—and this is an exciting finding that must be followed up. PrEP could be a powerful additional tool for some people who inject drugs,” said Mitchell Warren, AVAC executive director.

    13 June 2013 | AVAC press release

  • Study finds first evidence that PrEP can reduce HIV risk among people who inject drugs

    A daily dose of a medication used to treat HIV infection reduced the risk of HIV acquisition among people who inject drugs by 49 percent. Those who took the medication most consistently had even higher levels of protection, according to a new study announced today by the Centers for Disease Control and Prevention – in collaboration with the Bangkok Metropolitan Administration (BMA) and the Thailand Ministry of Public Health (MOPH).

    13 June 2013 | CDC press release

  • Mathematical models to better combat HIV

    In a paper titled "Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection," authors Jessica Conway, Bernhard Konrad, and Daniel Coombs present theoretical models of HIV dynamics immediately following exposure to the virus, thus providing a method to study infection and treatment at these early stages, as well as come up with preemptive strategies for prevention.

    03 June 2013 | Eurekalert Medicine & Health

  • Next steps for PrEP: Getting a proven prevention option to the people who need it

    Men and women need new prevention options that they can—and want—to use. For some people, that is a daily oral pill. But PrEP trials have taught us that biomedical tools have to work within the complex realities of people’s lives. The challenge is finding that marriage of need and desire to suit men’s and women’s lives, and then providing access to the right products at the right time.

    30 May 2013 | GMHC Treatment Issues

  • UK: Are you willing to take part in research that aims to reduce your risk of HIV?

    PROUD is a two-year study to recruit gay and bisexual men across England, who will be placed at random into one of two groups. One group will use PrEP from the start of the study, and the other group will receive PrEP after 12 months.

    16 May 2013 | PROUD study, UK Medical Research Council

  • This PrEP-ed Life: Damon Jacobs on Sex and Dating in a New Era of HIV Prevention

    As a licensed therapist working with people living with HIV, Damon Jacobs heard about pre-exposure prophylaxis (PrEP) as an HIV prevention strategy. When he found himself newly single after being out of the dating game for almost a decade, he re-entered a dating pool that was not at all condom-friendly. To deal with this, and to finally come to terms with his distaste for condoms, Damon began taking PrEP in July 2011 to stay HIV negative.

    14 May 2013 | TheBody.com

  • PrEP – Is this just a phase I’m going through?

    "How did I end up in this situation where I feel like I need PrEP?" The first of three blogs in which Marc-Andre le Blanc of IRMA answers his own question.

    18 April 2013 | MyPrEPExperience

  • Disappointing tenofovir PrEP trials: maybe “adherence” is not to blame

    Reports of modest success from two trials (2010) of tenofovir as pre-exposure prophylaxis against HIV (PrEP)– CAPRISA 004 (1) (topical gel/women) relative risk reduction (RRR) 39%; iPrEX (2) (oral tablet/MSM) RRR 44% – have inspired recent contributions to STI journal.

    29 March 2013 | BMJ Group blogs
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.